Broncho provocations for inhalation provocation tests
Perform inhalation provocation tests exceptionally fast and with reproducible results
Provo.X is a measuring station independent aerosol dosimeter developed by GANSHORN, which can perform specific or non-specific provocations within seconds. Due to the threshold-controlled and breath-synchronous application of the specified aerosol dose at the beginning of the inspiration phase, the results are optimally reproducible.
The optimal user guidance and simple handling of Provo.X makes the daily work easier for the staff. The most common protocols such as ATS or DGP are already installed. The aerosol dosimeter can store an unlimited number of protocols with up to 14 levels each. The dose per stage can be changed by increasing the provocation liquid concentration and/or by changing the total nebulization time.
The rear-vented special valve directly on the nebulizer and the large compressed air tank guarantee an optimal droplet size that remains constant over the entire bolus time. Furthermore, the individual adjustment of the nebulization time allows the use of only one aerosol concentration in many cases.
Advantages
- Individual dosage of the provocation material
- Individually adjustable nebulization time
- User-friendly LFX software
Features
Powerful compressor
The compressor with a three-liter compressed air tank guarantees stable nebulization pressure and low noise level (operating time of only about 3-5 minutes per week).
Optimal hygiene solution
All components of Provo.X that can be contaminated are designed for single use and do not need to be sterilized. This saves time and makes the Provo.X the only device on the market with a perfect hygienic solution.
Measurement principle
An FVC test is typically used for reference and post-provocation assessment. Other possible
measurements for a provocation sequence include:
– Offline parameter (manual input)
– No measurement (e.g., biomarkers)
– Body plethysmography
Each control module allows for specific measurements and can be used to determine the PD reference with percentage differences from the base or pre-measurements.
The patient inhales an aerosolized provocation substance using a nebulizer, taking slow, deep breaths. The substance is nebulized during the inspiratory cycle for a set bolus time. If inhalation is shorter than bolus time, the remaining time is added to the next breath. LFX monitors breathing and administers the aerosol only during inhalation, optimizing delivery and minimizing waste. The total dose per stage is automatically adjusted for short breathing cycles. As nebulization progresses, water vapor increases the concentration of the test substance, so the volume of the nebulizer solution should be increased accordingly.
After a set residence time (1-20 min), indicated
by a countdown, the user undergoes a body
plethysmography, spirometry or oscillometry
test. Then, the next provocation stage can
begin. This cycle of inhalation and control tests
repeats until all stages are completed or the
patient opts to stop.
For each control module, measurements can be
defined and used for the PD reference with
percentage differences from the base, such as
a 20% decrease in FEV1 or a 100% increase in
sRaw.
If after the last inhalation the FEV1 or alternative control parameter doesn’t fall below the threshold, the provocation test is regarded negative and asthma can be ruled out. If the threshold (PD20 in spirometry) is reached, the provocation should be stopped and the PD20 value of this positive provocation test is reported.
Set-Ups
with SpiroScout or PowerCube Spiro+
combination with
desktop spirometer
with PowerCube Diffusion+
combined with diffusion system
Stand alone device
with support arm and clamp for flexible mounting
in PowerCube Body+
for integrated use in
body box
Additional downloads
GANSHORN reserves the right to make changes in design, specifications and features shown, or discontinue the product described at any time without notice or obligation. Images may be representative. Device availability in your market is subject to regulatory approval.
